Notably, several loss-of-function mutations in the human HSD17B13 gene have been shown to confer strong anti-inflammatory and antifibrotic effects in the liver, and a few single-nucleotide polymorphisms in the HSD17B13 gene have also been associated with the development of NAFLD in humans [47]. Here, HSD17B13 is linked to metabolic dysfunction-associated steatotic liver disease.